Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
NCT ID: NCT03864978
Last Updated: 2019-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
236 participants
INTERVENTIONAL
2018-06-22
2020-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release versus placebo in adults with moderate-to-severe papulopustular rosacea (a.k.a. subtype II) and positive lactulose H2/CH4 breath test.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
NCT05150587
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
NCT03124199
Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication
NCT03925818
Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice.
NCT03150394
A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection
NCT03658733
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rifaximin-EIR 800 mg BID for 10 days
2 x rifaximin delayed release 400 mg tablet twice a day (total daily dose of rifaximin: 1600 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
Rifaximin delayed release 400 mg tablet
Rifaximin delayed release
Placebo
Placebo
Rifaximin-EIR 400 mg BID for 30 days
1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 30 days
Rifaximin delayed release 400 mg tablet
Rifaximin delayed release
Placebo
Placebo
Rifaximin-EIR 400 mg BID for 10 days
1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
Rifaximin delayed release 400 mg tablet
Rifaximin delayed release
Placebo
Placebo
Two placebo tablets BID for 30 days
2 x placebo tablets twice a day for 30 days
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rifaximin delayed release 400 mg tablet
Rifaximin delayed release
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female participants are eligible if they are either of non-childbearing potential or of childbearing potential with a negative pregnancy test result at screening and randomization and agreeing to use a highly effective method of contraception until 72 hours after taking the last study treatment dose.
3. Moderate-to-severe papulopustular rosacea (a.k.a. subtype II, RII) at screening and confirmed at randomization. Moderate-to-severe rosacea is defined as the presence of 11 or more facial papules or pustules with or without plaques.
4. Positivity of lactulose H2/CH4 breath test (L-BT) within the last 2-weeks before randomization.
5. Patients accepting to provide and legally capable of providing free and informed consent to all procedures included in the protocol (including facial skin photography).
Exclusion Criteria
2. Erythematoteleangectatic, phymatous or ocular rosacea only. Patients with these subtypes associated with papulopustular rosacea can be enrolled.
3. Circulating anti-helicobacter pylori IgM and/or IgG at screening (V1).
4. Positivity at the faecal Clostridium Difficile toxin assay at screening (V1).
5. History or family history of inflammatory bowel disease (Crohn's disease or ulcerative colitis) or other conditions characterized by severe intestinal ulcers.
6. History or family history of coeliac disease.
7. Patients with intestinal obstruction or partial intestinal obstruction.
8. Presence of diarrhoea associated with fever and/or blood in the stool.
9. Health conditions requiring continuous or intermittent treatment with facial topical, inhaled or systemic steroids and/or biologic or non-biologic immunosuppressive or immunomodulatory agents (e.g. autoimmune diseases, etc.).
10. Severe kidney impairment (i.e. estimated glomerular filtration rate \<30 ml/min).
11. Severe hepatic impairment (i.e. Child-Pugh B or C).
12. Cancer or any cancer-related treatment within 5 years prior to screening (excluding non-melanoma skin-cancer).
13. History of alcohol or drug abuse within a year prior to screening.
14. Facial skin conditions that can interfere with reliable assessment of rosacea throughout the study (e.g. keloids, hypertrophic scarring, recent facial surgery etc.)
15. Any other significant health condition (e.g. cardiovascular, respiratory, renal, hepatic, neurologic, psychiatric, hematologic, oncologic, immune etc.) that in the investigator's judgement may: i) jeopardize the patient's safe participation in the trial or ii) make unlikely the patient's completion of the study or iii) make unlikely the patient's compliance with the study procedures (e.g. highly anticipated need of non-permitted treatments, terminal illness, etc.).
16. History of hypersensitivity to rifaximin, rifamycin-derivatives, any of the rifaximin-EIR excipients, or any UV protection cream component.
17. Treatment with biologic immunomodulatory and/or immunosuppressive drugs (e.g. anti-TNF drugs) within 6 months prior to randomization.
18. Treatment with non-biologic immunomodulatory and/or immunosuppressive drugs (e.g. cyclosporine, methotrexate etc.) within 30 days prior to randomization.
19. Treatment with warfarin within 14 days prior to randomization.
20. Treatment with niacin within 30 days prior to randomization.
21. Topical facial or systemic antibiotics within 30 days before randomization;
22. Treatment with neomycin or other low-absorbable oral antibiotics (such as marketed rifaximin) within 90 days before randomization.
23. Topical facial, inhaled or systemic corticosteroids within 30 days prior to randomization.
24. Topical facial retinoids within 30 days before randomization.
25. Systemic retinoids within 6 months before randomization.
26. Any other topical or systemic treatment for rosacea within 30 days before randomization (including also laser and pulsed light, etc.).
27. Pharmaceutical prebiotics and probiotics (functional food is allowed), within 30 days before randomization.
28. Any experimental treatment within 6 months prior to randomization.
29. Women who are pregnant, breast-feeding or planning a pregnancy during the trial period.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alfasigma S.p.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedali Riuniti di Ancona
Ancona, , Italy
Policlinico di Bari
Bari, , Italy
Policlinico Sant'Orsola Malpighi
Bologna, , Italy
Spedali Civili
Brescia, , Italy
Policlinico Vittorio Emanuele
Catania, , Italy
Ospedale Policlinico San Martino
Genova, , Italy
Ospedale della Misericordia
Grosseto, , Italy
Policlinico di Modena
Modena, , Italy
Azienda Ospedaliera Universitaria Federico II
Napoli, , Italy
Policlinico Universitario A. Gemelli
Roma, , Italy
Azienda Ospedaliera Santa Maria
Terni, , Italy
A.O.U. Città della Salute e della Scienza
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-003722-33
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
REROS/001/17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.